Recruiting

Corticosteroid

Sponsor:

Methodist Health System

Code:

NCT05595031

Conditions

Covid 19

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.

Conditions

Covid 19

Study ID

NCT05595031

Start date

Oct 19, 2021

Status verified date

Oct, 2022

Completion date

Oct 19, 2023

Anticipated

Primary completion date

Oct 19, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • > 18 years of age
  • ICU admission at any time during first hospital admission for COVID-19
  • COVID-19 diagnosis
  • Dexamethasone, hydrocortisone, or methylprednisolone therapy for SARS-CoV-2 infection

Exclusion Criteria:

  • Prior ICU admission before study start date
  • Death or hospice before day 11 of hospital admission
  • Still admitted at time of data analysis from index admission

Study Design

Enrollment

400 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • All-cause in-hospital mortality at 28 days [ Time Frame: 28 days ]

Central Contacts and Locations

Central contacts

Crystee Cooper, DHEd

214-947-1280clinicalresearch@mhd.com

Zaid Haddadin, MS

214-947-1280clinicalresearch@mhd.com

Locations

Methodist Dallas Medical Center

Recruiting

Dallas, Texas, United States, 75052

Contacts

Crystee Cooper, DHEd

214-947-1280clinicalresearch@mhd.com

Zaid Haddadin, MS

2149471280clinicalresearch@mhd.com

Principal Investigator:

Kristen Rahmanzadeh, Pharm D

More Information

Sponsor

Methodist Health System

Last update posted

Oct 26, 2022

Last verified

Oct, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Methodist Health System on 2022-10-26.